These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 35403528)

  • 1.
    Mirahmad M; Sabourian R; Mahdavi M; Larijani B; Safavi M
    Drug Metab Rev; 2022 May; 54(2):161-193. PubMed ID: 35403528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury.
    Proctor WR; Foster AJ; Vogt J; Summers C; Middleton B; Pilling MA; Shienson D; Kijanska M; Ströbel S; Kelm JM; Morgan P; Messner S; Williams D
    Arch Toxicol; 2017 Aug; 91(8):2849-2863. PubMed ID: 28612260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of human drug-induced liver injury (DILI) in relation to oral doses and blood concentrations.
    Albrecht W; Kappenberg F; Brecklinghaus T; Stoeber R; Marchan R; Zhang M; Ebbert K; Kirschner H; Grinberg M; Leist M; Moritz W; Cadenas C; Ghallab A; Reinders J; Vartak N; van Thriel C; Golka K; Tolosa L; Castell JV; Damm G; Seehofer D; Lampen A; Braeuning A; Buhrke T; Behr AC; Oberemm A; Gu X; Kittana N; van de Water B; Kreiling R; Fayyaz S; van Aerts L; Smedsrød B; Ellinger-Ziegelbauer H; Steger-Hartmann T; Gundert-Remy U; Zeigerer A; Ullrich A; Runge D; Lee SML; Schiergens TS; Kuepfer L; Aguayo-Orozco A; Sachinidis A; Edlund K; Gardner I; Rahnenführer J; Hengstler JG
    Arch Toxicol; 2019 Jun; 93(6):1609-1637. PubMed ID: 31250071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A human liver organoid screening platform for DILI risk prediction.
    Zhang CJ; Meyer SR; O'Meara MJ; Huang S; Capeling MM; Ferrer-Torres D; Childs CJ; Spence JR; Fontana RJ; Sexton JZ
    J Hepatol; 2023 May; 78(5):998-1006. PubMed ID: 36738840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A high content screening assay to predict human drug-induced liver injury during drug discovery.
    Persson M; Løye AF; Mow T; Hornberg JJ
    J Pharmacol Toxicol Methods; 2013; 68(3):302-13. PubMed ID: 23933113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Vitro Models for Studying Chronic Drug-Induced Liver Injury.
    Donato MT; Gallego-Ferrer G; Tolosa L
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism-based integrated assay systems for the prediction of drug-induced liver injury.
    Kawaguchi M; Nukaga T; Sekine S; Takemura A; Susukida T; Oeda S; Kodama A; Hirota M; Kouzuki H; Ito K
    Toxicol Appl Pharmacol; 2020 May; 394():114958. PubMed ID: 32198022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three-dimensional culture of hepatocytes for prediction of drug-induced hepatotoxicity.
    Meng Q
    Expert Opin Drug Metab Toxicol; 2010 Jun; 6(6):733-46. PubMed ID: 20380484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of Drug-Induced Hepatotoxicity Using Long-Term Stable Primary Hepatic 3D Spheroid Cultures in Chemically Defined Conditions.
    Vorrink SU; Zhou Y; Ingelman-Sundberg M; Lauschke VM
    Toxicol Sci; 2018 Jun; 163(2):655-665. PubMed ID: 29590495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of drug-induced liver injury and cardiotoxicity using chemical structure and in vitro assay data.
    Ye L; Ngan DK; Xu T; Liu Z; Zhao J; Sakamuru S; Zhang L; Zhao T; Xia M; Simeonov A; Huang R
    Toxicol Appl Pharmacol; 2022 Nov; 454():116250. PubMed ID: 36150479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro assessment of farnesoid X receptor antagonism to predict drug-induced liver injury risk.
    Norona LM; Fullerton A; Lawson C; Leung L; Brumm J; Kiyota T; Maher J; Khojasteh C; Proctor WR
    Arch Toxicol; 2020 Sep; 94(9):3185-3200. PubMed ID: 32583097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolomics-based strategy to assess drug hepatotoxicity and uncover the mechanisms of hepatotoxicity involved.
    Martínez-Sena T; Moro E; Moreno-Torres M; Quintás G; Hengstler J; Castell JV
    Arch Toxicol; 2023 Jun; 97(6):1723-1738. PubMed ID: 37022445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A testing strategy to predict risk for drug-induced liver injury in humans using high-content screen assays and the 'rule-of-two' model.
    Chen M; Tung CW; Shi Q; Guo L; Shi L; Fang H; Borlak J; Tong W
    Arch Toxicol; 2014 Jul; 88(7):1439-49. PubMed ID: 24958025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioprinted 3D Primary Liver Tissues Allow Assessment of Organ-Level Response to Clinical Drug Induced Toxicity In Vitro.
    Nguyen DG; Funk J; Robbins JB; Crogan-Grundy C; Presnell SC; Singer T; Roth AB
    PLoS One; 2016; 11(7):e0158674. PubMed ID: 27387377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advancing Predictive Hepatotoxicity at the Intersection of Experimental, in Silico, and Artificial Intelligence Technologies.
    Fraser K; Bruckner DM; Dordick JS
    Chem Res Toxicol; 2018 Jun; 31(6):412-430. PubMed ID: 29722533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An integrated biomimetic array chip for establishment of collagen-based 3D primary human hepatocyte model for prediction of clinical drug-induced liver injury.
    Xiao RR; Lv T; Tu X; Li P; Wang T; Dong H; Tu P; Ai X
    Biotechnol Bioeng; 2021 Dec; 118(12):4687-4698. PubMed ID: 34478150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current challenges and controversies in drug-induced liver injury.
    Corsini A; Ganey P; Ju C; Kaplowitz N; Pessayre D; Roth R; Watkins PB; Albassam M; Liu B; Stancic S; Suter L; Bortolini M
    Drug Saf; 2012 Dec; 35(12):1099-117. PubMed ID: 23137150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current limitations and future opportunities for prediction of DILI from in vitro.
    Funk C; Roth A
    Arch Toxicol; 2017 Jan; 91(1):131-142. PubMed ID: 27766365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro evaluation of potential hepatotoxicity induced by drugs.
    Gómez-Lechón MJ; Lahoz A; Gombau L; Castell JV; Donato MT
    Curr Pharm Des; 2010 Jun; 16(17):1963-77. PubMed ID: 20236064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three-dimensional (3D) liver cell models - a tool for bridging the gap between animal studies and clinical trials when screening liver accumulation and toxicity of nanobiomaterials.
    Tutty MA; Movia D; Prina-Mello A
    Drug Deliv Transl Res; 2022 Sep; 12(9):2048-2074. PubMed ID: 35507131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.